Effects of topiramate on weight and metabolism in children with epilepsy
Hai-feng Li1, Yan Zou, Zhe-zhi Xia
1The Children's Hospital Zhejiang University School of Medicine, Hangzhou, China.
Insights
Topiramate treatment in children with epilepsy enhances energy metabolism, leading to weight loss. This effect is linked to increased adiponectin levels, a key metabolic regulator.
Area of Science:
- Pediatric Neurology
- Metabolic Research
- Pharmacology
Background:
- Epilepsy affects children globally, with some antiepileptic drugs causing weight changes.
- Understanding the metabolic impact of antiepileptic drugs like topiramate is crucial for patient management.
Purpose of the Study:
- To investigate the metabolic mechanisms underlying topiramate-induced weight loss in pediatric epilepsy patients.
- To assess changes in key metabolism indices following topiramate treatment.
Main Methods:
- A cohort of children with epilepsy received topiramate treatment.
- Metabolism indices, including BMI, leptin, adiponectin, leptin/adiponectin ratio, and HOMA index, were measured before and after treatment.
Main Results:
- Topiramate significantly reduced the leptin/adiponectin ratio (p=0.031).
- Serum adiponectin levels were markedly increased (p=0.002).
- No correlation was found between metabolism indices and topiramate dosage (p>0.05).
Conclusions:
- Topiramate treatment in epilepsy children promotes weight loss by enhancing energy metabolism.
- Adiponectin plays a significant role in the metabolic regulation observed during topiramate therapy.
Aim:
To explore the mechanism of topiramate-induced weight loss in epilepsy children by monitoring metabolism indices.
Methods:
Children with epilepsy were treated with topiramate at their first clinical visit. Metabolism indices including body mass index (BMI) and its SD scores, leptin, adiponectin, leptin/adiponectin (L/A), lipid profile-insulin and Homeostasis Model Assessments (HOMA) index were collected before and after treatment.
Results:
Topiramate treatment significantly reduced L/A (t = 2.156, p = 0.031), and markedly increased the serum level of adiponectin (t = 3.124, p = 0.002). Moreover, there were no relationships between the metabolism indices and dosages of topiramate (p > 0.05).
Conclusion:
Our studies find that topiramate treatment in epilepsy children increases energy metabolism, resulting in weight loss. It has been demonstrated that adiponectin play a significant role in metabolic regulations.
Related Concept Videos
Antiepileptic Drugs: Glutamate Antagonists
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Epilepsy and Seizures: Overview
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Antiepileptic Drugs: Calcium Channel Blockers
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...

